The genetic landscape of diffuse large B-cell lymphoma.
The genetic landscape of diffuse large B-cell lymphoma.
复制标题
DOI：
10.1053/j.seminhematol.2015.01.005
复制
发表时间：
2015-04
影响因子：
3.6
通讯作者：
Dalla-Favera R
中科院分区：
文献类型：
--
作者：
Pasqualucci L;Dalla-Favera R
弥漫性大B细胞淋巴瘤(DLBCL)是西方世界最常见的淋巴系统恶性肿瘤，是一种侵袭性疾病，约30%的患者仍无法治愈。在过去的十年中，测序技术的快速发展使得基因组和转录变化的评估成为可能，通过提供一个全面和公正的视角来了解DLBCL的遗传基础，我们对这种疾病的基因/途径进行了全面和公正的观察，并可能有助于肿瘤的启动和扩展。这些研究发现，在关键细胞通路中存在几个以前未被认识到的变化，这些变化也可能影响治疗结果。事实上，一些新发现的遗传损伤目前正在探索，作为改善诊断和风险分层的标志，或正在进入临床试验，作为有希望的治疗目标。本文综述了DLBCL基因组特征的最新进展，并讨论了从这些努力中获得的信息如何为其生物学提供了新的见解，揭示了与预后和治疗相关的潜在靶点。
Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in the western world, is an aggressive disease that remains incurable in approximately 30% of patients. Over the past decade, the rapid expansion of sequencing technologies allowing the genome-wide assessment of genomic and transcriptional changes has revolutionized our understanding of the genetic basis of DLBCL by providing a comprehensive and unbiased view of the genes/pathways that are disrupted by genetic alterations in this disease, and may contribute to tumor initiation and expansion. These studies uncovered the existence of several previously unappreciated alterations in key cellular pathways that may also influence treatment outcome. Indeed, a number of newly identified genetic lesions are currently being explored as markers for improved diagnosis and risk stratification, or are entering clinical trials as promising therapeutic targets. This review focuses on recent advances in the genomic characterization of DLBCL and discusses how information gained from these efforts has provided new insights into its biology, uncovering potential targets of prognostic and therapeutic relevance.